SAR405838

DRUG2 trials

Sponsors

Sanofi

Conditions

Neoplasm Malignant

Phase 1

Phase 1 Safety Testing of SAR405838

CompletedNCT01636479

SanofiNeoplasm Malignant

Start: 2012-07-13End: 2018-03-05Updated: 2018-05-17

A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients

CompletedNCT01985191

SanofiNeoplasm Malignant

Start: 2013-11-30End: 2016-02-29Updated: 2016-02-25

Related Papers

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

2018-12-2641 citations

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.

2017-03-1799 citations

Fortifying p53 – beyond Mdm2 inhibitors

Aging2016-09-296 citations